Physician profile
Manuel Antonio Suarez Barcelo
NPI 1669461042
$175,370.99
in general payments reported to CMS, 2019-2025
24 companies · $5,165 in 2025
The $5,165 reported for 2025 was more than what 98% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $49K · 2020: $13K · 2021: $21K · 2022: $39K · 2023: $28K · 2024: $20K · 2025: $5,165.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $30K · Travel and Lodging: $11K · Consulting Fee: $9,293 · Food and Beverage: $2,820.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $29,640.53 |
| Travel and Lodging | $11,290.04 |
| Consulting Fee | $9,292.50 |
| Food and Beverage | $2,820.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Urovant Sciences INC | $46,033.28 | 2021-2022 | |
| Lilly USA, LLC | $37,246.75 | 2019-2025 | Zepbound, Mounjaro, Amyvid |
| Sunovion Pharmaceuticals INC. | $23,010.65 | 2019-2020 | |
| Sumitomo Pharma America, INC. | $22,459.85 | 2023-2024 | Gemtesa |
| Mylan Specialty L.P. | $21,626.96 | 2019-2024 | Yupelri, Yupelri |
| Mylan INC. | $12,056.27 | 2019-2021 | |
| Xeris Pharmaceuticals, INC. | $6,762.01 | 2023 | Gvoke Hypopen |
| Viatris Specialty LLC | $4,844.28 | 2025 | Yupelri |
| Bayer Healthcare Pharmaceuticals INC. | $273.51 | 2022-2025 | |
| Amgen INC. | $214.80 | 2019-2025 | Repatha, Otezla, Repatha |
| Otsuka America Pharmaceutical, INC. | $154.08 | 2023-2024 | Rexulti |
| Glaxosmithkline, LLC. | $113.52 | 2023-2024 | Arexvy, Shingrix, Trelegy Ellipta |
| Exact Sciences Corporation | $96.46 | 2023-2025 | Cologuard Collection Kit |
| Avanir Pharmaceuticals, INC. | $93.10 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $89.38 | 2019-2025 | Austedo Xr, Austedo Xr |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $75.15 | 2019-2024 | |
| Astrazeneca Pharmaceuticals Lp | $49.92 | 2021 | |
| Eisai INC. | $34.53 | 2022 | |
| Sun Pharmaceutical Industries INC. | $24.90 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $24.64 | 2025 | Caplyta |
| Pfizer INC. | $23.78 | 2025 | |
| Janssen Pharmaceuticals, INC | $23.54 | 2023 | Xarelto |
| Cvrx, INC. | $21.40 | 2023 | Barostim Neo System |
| Mannkind Corporation | $18.23 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Manuel Suarez Barcelo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.